User:Mr. Ibrahem/Nilotinib

Nilotinib, sold under the brand name Tasigna, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. It is taken by mouth.

Common side effects may include low platelets, low white blood cells, anemia, rashes, vomiting, diarrhea, and joint pains. Other serious side effects may include QT prolongation, sudden death, pancreatitis, and liver problems. It is not safe for use during pregnancy. Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell.

Nilotinib was approved for medical use in the United States in 2007. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom it costs the NHS £2,433 per month as of 2018. In the United States this amount costs US$14,368 as of 2019.